Cannabinoids possess a variety of pharmacological properties through interaction with two Gprotein coupled receptors (i.e. CB1 and CB2). The CB1 receptor is primarily expressed in the nervous system where as the CB2 receptor is mainly expressed in periphery. Unlike the CB1 receptor, activation of CB2 receptor does not produce a psychotropic effect. The biomedical research field has strived to discover high affinity, selective CB2 agonists for the treatment of variety of disorders including pain, cancer and neurodegenerative diseases. A large number of CB2 selective ligands have been discovered over last two decades. In this project, we set forth to develop novel lead compounds as potential CB2 selective agonists from scaffolds of bispentyloxy- benzamide identified by Japan Tabaco Inc. The designed molecules include bispentyloxy- indole-2-carboxamide and bis-pentyloxy-2H-chromene-3-carboxamide, of which the former scaffold was accessed by Hametsberger-Knittel and Japp-Klingemann reactions respectively, the later one was obtained from aldol condensation followed by lactone formation.
September 29, 2015
The right to download or print any of the pages of this thesis (Material) is granted by the copyright owner only for personal or classroom use. The author retains all proprietary rights, including copyright ownership. Any reproduction or editing or other use of this Material by any means requires the express written permission of the copyright owner. Except as provided above, or any use beyond what is allowed by fair use (Title 17 Section 107 U.S.C.), you may not reproduce, republish, post, transmit or distribute any Material from this web site in any physical or digital form without the permission of the copyright owner of the Material. Inquiries regarding any further use of these materials should be addressed to Administration, Jernigan Library, Texas A&M University-Kingsville, 700 University Blvd. Kingsville, Texas 78363-8202, (361)593-3416.